Evidence map›Paper›PMID 30003620›Full record

ArticleAdvanced materials (Deerfield Beach, Fla.)2018

Tracking the Fate of Porous Silicon Nanoparticles Delivering a Peptide Payload by Intrinsic Photoluminescence Lifetime.

Yusung Jin, Dokyoung Kim, Hajung Roh, Sojeong Kim, Sazid Hussain, Jinyoung Kang, Chan-Gi Pack, Jun Ki Kim, Seung-Jae Myung, Erkki Ruoslahti and 3 more

Abstract read
In one paragraph

Article in Advanced materials (Deerfield Beach, Fla.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Porous silicon and silica carriers for delivery of peptide therapeutics.Drug delivery and translational research · 2024
    Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yusung JinBiomedical Engineering Research Center, Asan Institute for Life Sciences, Asan Medical Center, Seoul, 05505, Republic of Korea.
Dokyoung KimDepartment of Anatomy and Neurobiology, College of Medicine, and Biomedical Science Institute, Kyung Hee University, Seoul, 02447, Republic of Korea.ORCID http://orcid.org/0000-0002-7756-3560
Hajung RohBiomedical Engineering Research Center, Asan Institute for Life Sciences, Asan Medical Center, Seoul, 05505, Republic of Korea.
Sojeong KimBiomedical Engineering Research Center, Asan Institute for Life Sciences, Asan Medical Center, Seoul, 05505, Republic of Korea.
Sazid HussainCancer Research Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, 92037, USA.
Jinyoung KangDepartment of Nanoengineering, University of California, San Diego, La Jolla, CA, 92093, USA.
Chan-Gi PackDepartment of Convergence Medicine, Asan Medical Center and University of Ulsan College of Medicine, Seoul, 05505, Republic of Korea.
Jun Ki KimBiomedical Engineering Research Center, Asan Institute for Life Sciences, Asan Medical Center, Seoul, 05505, Republic of Korea.
Seung-Jae MyungDepartment of Gastroenterology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, 05505, Republic of Korea.
Erkki RuoslahtiCancer Research Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, 92037, USA.
Michael J SailorDepartment of Nanoengineering, University of California, San Diego, La Jolla, CA, 92093, USA.ORCID http://orcid.org/0000-0002-4809-9826
Song Cheol KimBiomedical Engineering Research Center, Asan Institute for Life Sciences, Asan Medical Center, Seoul, 05505, Republic of Korea.
Jinmyoung JooBiomedical Engineering Research Center, Asan Institute for Life Sciences, Asan Medical Center, Seoul, 05505, Republic of Korea.

Funding

Macrophage-targeting Nanoplatforms as Immunotherapy against Pulmonary InfectionsR01AI132413 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Michael J Sailor · 2017 to 2026
$6.0M
Single domain antibody development for improving vascular dysfunction in Alzheimer’s diseaseR44AG097127 · NIA · AIVOCODE, LLP · PI Sazid Hussain · 2025 to 2026
$2.5M
Tumor Penetrating Peptides for Cancer TargetingR01CA152327 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI RUOSLAHTI, ERKKI · 2011 to 2015
$2.0M
Improving the in Vivo Delivery and Antitumor Efficacy of Antisense DrugsR01CA214550 · NCI · UNIVERSITY OF MINNESOTA · PI PANG, HONGBO · 2017 to 2021
$1.7M
Novel Therapeutic Agent for Reversing Vascular Dysfunction in Alzheimer's DiseaseR43AG071399 · NIA · AIVOCODE, LLP · PI HUSSAIN, SAZID · 2021 to 2021
$434k
Asan Institute for Life Sciences, Asan Medical CenterKorea Health Industry Development Institute (KHIDI) HI14C1090Korea Health Technology R&D ProjectMinistry of Education 2017R1D1A1B03035525Ministry of Education NRF-2018R1A6A1A03025124Ministry of Science and ICT 2016-7016Ministry of Science and ICT 2017-7016Ministry of Science and ICT 2017M3A9C6032056Ministry of Science and ICT 2018-7016Ministry of Science and ICT 2018-7045National Research Foundation of KoreaNational Science Foundation CBET-1603177NCI NIH HHS R01 CA152327NCI NIH HHS R01 CA214550NIAID NIH HHS R01 AI132413NIA NIH HHS R43 AG071399NIA NIH HHS R44 AG097127NIH HHS R01 AI132413-01NIH HHS R01 CA152327NIH HHS R01 CA214550
6 · The paper itself

Abstract

A nanoparticle system for systemic delivery of therapeutics is described, which incorporates a means of tracking the fate of the nanocarrier and its residual drug payload in vivo by photoluminescence (PL). Porous silicon nanoparticles (PSiNPs) containing the proapoptotic antimicrobial peptide payload,

Indexed as

NanoparticlesAnimalsLuminescenceMicePeptidesPorositySiliconPeptidesSiliconbiodegradationbioimagingphotoluminescence lifetimetheranosticstime-gated luminescence imaging

Identifiers

PMID30003620
PMCPMC6177232

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.